Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 113, Issue 3, 2013, Pages 397-401

  Santoni, Matteo ^a   Scoccianti, Silvia ^b   Lolli, Ivan ^c   Fabrini, Maria Grazia ^d   Silvano, Giovanni ^e   Detti, Beatrice ^b   Perrone, Franco ^d   Savio, Giuseppina ^f   Iacovelli, Roberto ^g   Burattini, Luciano ^a   Berardi, Rossana ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e Radioterapia Oncologica SG Moscati Hospital   (Italy)

^f UO di Anatomia Patologica   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Elderly patients; Fotemustine; Glioblastoma; Safety; Temozolomide

Indexed keywords

FOTEMUSTINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84879416141     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1125-3     Document Type: Article

References (22)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14:1-49
2. Chinot OL (2003) Should radiotherapy be standard therapy for brain tumors in the elderly? Cons. Semin Oncol 30(6):68-71
3. Lopez S, Taillibert S, Idbaih A, Simon JM, Mazeron JJ (2008) Should elderly patients with glioblastoma be proposed to radiotherapy? Cancer Radiother 12:827-830
4. Wick W, Platten M, Meisner C, Felsberg J, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715
5. Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol 107:395-405
6. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
7. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512-3518
8. Kimple RJ, Grabowski S, Papez M, Collichio F, Ewend MG, Morris DE (2010) Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? Am J Clin Oncol 33:265-270
9. Fiorica F, Berretta M, Colosimo C, Stefanelli A, Ursino S, Zanet E, Palmucci T, Maugeri D, Malaguarnera M, Palmucci S, Grasso M, Tirelli U, Cartei F (2010) Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 51:31-35
10. Shikama N, Sasaki S, Shinoda A, Koiwai K (2012) Treatment outcome of elderly patients with glioblastoma who received combination therapy. Am J Clin Oncol 35:486-489
11. Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, Iwamoto FM (2012) Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 109:391-397
12. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83:93-99
13. Malhaire JP, Lucas B, Simon H, Person H, Dam-Hieu P, Labat JP (1999) Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull Cancer 86:289-294
14. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amista P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64:769-775
15. Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L, Ammannati F, Biti G (2008) Second-line chemotherapy with fotemustine in temozolomide- pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19:613-620
16. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L (2009) A multi-institutional phase II study on second line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92:79-86
17. Paccapelo A, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Santoni M, Bonizzoni E, Perrone T, Scoccianti S (2012) A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. J Transl Med 10:90. doi: 10.1186/1479-5876-10-90
18. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
19. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R: Nordic Clinical Brain Tumour Study Group (NCBTSG) (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916-926
20. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715
21. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the rescue approach. Cancer 113:2152-2157
22. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740